The Codagenix oncolytic has demonstrated efficacy in models of melanoma.
Over 190,000 cases of melanoma are diagnosed each year. In the last ten years, the number of new melanoma cases increased by 54%. Current oncolytic therapies against melanoma cannot prevent metastases or prolong survival of patients, highlighting the need for new therapies. In animal models, the Codagenix oncolytic successfully reduced the size of primary tumors and prevented recurrence of disease.
New cases diagnosed
Increase in melanoma cases
In the past 10 years